VKTX: Viking Therapeutics, Inc.
About
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Current Value
$52.701 Year Return
Current Value
$52.701 Year Return
Key Details
Market Cap
$5.74B
P/E Ratio
-55
1Y Stock Return
353.83%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
6.3
Strategies that include VKTX
Stock's related to VKTX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DNLI | 54.80% | $3.50B | +33.66% | 0.00% |
| LGND | 49.69% | $2.11B | +91.18% | 0.00% |
| AHCO | 42.73% | $1.31B | +17.07% | 0.00% |
| PUBM | 42.43% | $739.82M | -2.82% | 0.00% |
| BEAM | 42.26% | $2.09B | -9.52% | 0.00% |
| DORM | 41.95% | $4.14B | +89.68% | 0.00% |
| STRL | 41.89% | $5.93B | +200.06% | 0.00% |
| CEG | 39.82% | $73.37B | +91.48% | 0.59% |
| AKRO | 39.16% | $2.17B | +93.09% | 0.00% |
| ALT | 37.12% | $531.30M | +194.09% | 0.00% |
| ERIE | 36.79% | $19.39B | +46.23% | 1.23% |
| HSII | 36.79% | $914.74M | +64.66% | 1.35% |
| HIMS | 36.09% | $5.14B | +210.42% | 0.00% |
| TARS | 35.24% | $1.79B | +166.88% | 0.00% |
| CGBD | 34.68% | - | - | 9.47% |
| STOK | 34.37% | $614.95M | +197.69% | 0.00% |
| DRS | 34.16% | $9.28B | +88.06% | 0.00% |
| DAWN | 31.96% | $1.36B | +13.42% | 0.00% |
| SSD | 30.53% | $7.54B | +11.68% | 0.62% |
| XHR | 30.50% | $1.51B | +19.71% | 3.13% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CSTM | -0.01% | $1.70B | -32.91% | 0.00% |
| HSTM | -0.02% | $980.58M | +26.38% | 0.43% |
| CMTL | 0.04% | $84.44M | -76.16% | 0.00% |
| QNST | 0.05% | $1.19B | +93.14% | 0.00% |
| STZ | -0.08% | $43.65B | +2.63% | 1.64% |
| IRS | -0.11% | $1.22B | +117.95% | 4.11% |
| WTW | 0.11% | $30.98B | +26.60% | 1.13% |
| BERY | 0.11% | $7.61B | +12.08% | 1.61% |
| VLO | -0.11% | $44.96B | +15.30% | 2.28% |
| FMC | 0.11% | $6.94B | +4.53% | 4.17% |
| VSTA | -0.12% | $204.94M | -39.33% | 0.00% |
| PTVE | -0.14% | $2.25B | +12.14% | 3.19% |
| EMBC | -0.15% | $777.82M | -20.98% | 4.49% |
| ARMK | 0.16% | $9.93B | +35.19% | 1.01% |
| STE | -0.16% | $20.93B | +5.37% | 1.28% |
| ZH | 0.17% | $333.09M | -40.59% | 0.00% |
| GAN | 0.18% | $83.39M | +21.19% | 0.00% |
| UEIC | 0.18% | $148.52M | +43.22% | 0.00% |
| COP | -0.20% | $130.16B | -1.63% | 2.59% |
| PFE | -0.20% | $142.24B | -17.16% | 6.73% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NERV | -45.91% | $14.69M | -58.00% | 0.00% |
| PRGO | -37.08% | $3.72B | -9.95% | 4.04% |
| STGW | -36.37% | $832.16M | +51.63% | 0.00% |
| FSK | -25.62% | - | - | 11.89% |
| AJX | -25.14% | $137.63M | -33.99% | 9.24% |
| EFC | -22.12% | $1.12B | -4.48% | 13.28% |
| DK | -20.01% | $1.14B | -34.04% | 5.64% |
| HLX | -16.35% | $1.60B | +13.04% | 0.00% |
| IFF | -15.00% | $22.74B | +20.83% | 2.25% |
| SCKT | -14.60% | $10.88M | +15.32% | 0.00% |
| PRGS | -14.24% | $2.82B | +23.36% | 1.06% |
| WLKP | -14.05% | $796.39M | +4.00% | 8.34% |
| SIBN | -14.04% | $516.68M | -29.40% | 0.00% |
| IMXI | -13.86% | $651.21M | -1.55% | 0.00% |
| ASUR | -13.49% | $233.14M | +12.13% | 0.00% |
| IMRN | -13.16% | $10.31M | -5.04% | 0.00% |
| HES | -12.59% | $45.06B | +1.32% | 1.24% |
| CMLS | -11.53% | $13.08M | -84.44% | 0.00% |
| ROL | -11.35% | $23.98B | +23.53% | 1.25% |
| SBAC | -11.22% | $23.60B | -6.03% | 1.80% |
ETF's related to VKTX
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 45.10% | $6.58B | 0.35% |
| PTH | 40.82% | $143.31M | 0.6% |
| GNOM | 29.38% | $70.59M | 0.5% |
| QQA | 28.13% | $135.01M | 0% |
| RSPA | 27.50% | $273.87M | 0% |
| ITEQ | 26.60% | $84.84M | 0.75% |
| IBB | 26.10% | $6.66B | 0.45% |
| FPX | 25.88% | $797.15M | 0.59% |
| IWO | 25.72% | $12.56B | 0.24% |
| ISCG | 25.41% | $640.00M | 0.06% |
| PBE | 25.02% | $258.53M | 0.58% |
| ARKG | 24.82% | $1.13B | 0.75% |
| IBUY | 23.85% | $176.17M | 0.65% |
| IWC | 23.85% | $933.99M | 0.6% |
| HDRO | 23.70% | $164.26M | 0.3% |
| IPO | 23.65% | $157.08M | 0.6% |
| VBK | 23.51% | $19.31B | 0.07% |
| NUSC | 23.49% | $1.27B | 0.31% |
| FSMD | 23.45% | $583.89M | 0.15% |
| PINK | 23.04% | $161.15M | 0.5% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BSCW | 0.03% | $635.46M | 0.1% |
| LQDW | -0.08% | $206.97M | 0.34% |
| TIP | -0.08% | $16.12B | 0.19% |
| XMPT | -0.13% | $230.08M | 1.98% |
| UITB | -0.13% | $2.36B | 0.38% |
| BGRN | 0.19% | $389.17M | 0.2% |
| DBA | 0.20% | $755.88M | 0.93% |
| IBDW | 0.21% | $1.18B | 0.1% |
| FLDR | 0.22% | $595.01M | 0.15% |
| SHAG | -0.23% | $33.13M | 0.12% |
| TDTF | 0.23% | $719.61M | 0.18% |
| CORP | -0.24% | $1.25B | 0.23% |
| LMBS | 0.28% | $4.62B | 0.64% |
| IVOL | 0.28% | $548.70M | 1.02% |
| BUXX | -0.29% | $162.67M | 0.25% |
| PFLD | 0.29% | $457.09M | 0.46% |
| MUNI | 0.36% | $1.73B | 0.35% |
| GTIP | -0.37% | $136.50M | 0.12% |
| MINT | -0.39% | $11.62B | 0.35% |
| BSCV | 0.41% | $673.58M | 0.1% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -23.74% | $388.04M | 1.43% |
| VIXY | -12.86% | $195.31M | 0.85% |
| TAIL | -11.91% | $67.98M | 0.59% |
| IBD | -10.91% | $330.68M | 0.44% |
| BSCO | -7.97% | $2.35B | 0.1% |
| KCCA | -7.42% | $220.51M | 0.87% |
| FTSM | -7.35% | $6.08B | 0.45% |
| BAB | -6.84% | $1.06B | 0.28% |
| USDU | -6.77% | $201.97M | 0.5% |
| BOND | -6.76% | $5.01B | 0.58% |
| XHLF | -6.58% | $874.27M | 0.03% |
| SMMU | -6.49% | $624.12M | 0.35% |
| TPMN | -6.31% | $40.60M | 0.65% |
| SGOV | -6.14% | $27.53B | 0.09% |
| SHV | -5.91% | $18.13B | 0.15% |
| VNLA | -5.84% | $2.27B | 0.23% |
| KMLM | -5.81% | $353.87M | 0.9% |
| SMB | -5.79% | $266.77M | 0.07% |
| UUP | -5.60% | $309.25M | 0.77% |
| FTSD | -5.48% | $171.68M | 0.25% |
News
Yahoo
On Tuesday, Viking Therapeutics, Inc. (NASDAQ:VKTX) highlighted the final results from its VOYAGE Phase 2b trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also referred to as metabolic dysfunction-associated steatohepatitis, MASH) at the American Association for the Study of Liver Disease. Reduction in Liver Fat Content at 52 Weeks: Patients receiving VK2809 demonstrated statistically significant reductions in liver fat at Week 12, the primary endpoint. Pat
Finnhub
SAN DIEGO - Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that final...
Yahoo
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that final results from the company's Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH; also referred to as metabolic dysfunction associated steatohepatitis, MASH) were hig
Finnhub
NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. . Such investors are advised to contact Danielle Peyton at...
Yahoo
There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its clinical-stage candidate for weight loss, there's a real chance that this competitor could see its shares soar for years. Let's examine three things you'll need to factor into your decision if you plan on investing in Viking Therapeutics today.
Yahoo
Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech that rose in prominence this year. Is it too late to invest in Viking Therapeutics, or do the company's shares remain attractive? There could be plenty of upside for Viking Therapeutics.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.